title: Impact of porcine circovirus type 2 (PCV2) vaccination on boar semen quality and quantity using two different vaccines.
abstract: Porcine circovirus type-2 (PCV2) is widespread in domestic pig populations. It can be shed with boar semen, but the role boars have in epidemiology is still unclear. Vaccinating boars against PCV2 can reduce disease and virus load in semen, but may have unwanted side effects, that is, impairment of spermatogenesis. Therefore, the aim of this study was to investigate the effect and impact of two different PCV2 vaccines on boar semen quality and quantity. Healthy normospermic Large White boars in three groups of 12 each were vaccinated with either Circovac, Ingelvac CircoFLEX, or received NaCl. Eight ejaculates were collected starting 1 week after vaccination and assessed for quantitative traits. In general, sperm quantity and quality parameters did not change due to the vaccination (P > 0.05). Only DNA integrity between the Circovac and control group was P < 0.05 but remained at a low level (<2%). One boar showed clinical signs with body temperature up to 39.9 °C and went off feed. For this animal, a clear relation between vaccination, fever period, and impaired sperm quality could be observed. The results indicate that both vaccines did not have a major impact on sperm quality or quantity. Therefore, vaccination of boars against PCV2 seems to be feasible. However, one boar treated with the oil-based vaccine showed a temporarily impaired semen quality after elevated body temperature after vaccination. Thus, possible systemic reactions and the subsequent impact on sperm quality should be taken into account when choosing a PCV2 vaccine for boars.
authors: SUISAG, Sempach, Switzerland. Electronic address: caspari@kuemmerlencaspari.ch.
authors: K
authors: K
authors: Caspari
authors: University of Utrecht, Faculty of Veterinary Medicine, Department of Equine Science - Reproduction, Utrecht, The Netherlands.
authors: H
authors: H
authors: Henning
authors: Boehringer Ingelheim Animal Health GmbH, Basel, Switzerland.
authors: F
authors: F
authors: Schreiber
authors: Boehringer Ingelheim Pharma GmbH & Co KG, BDM, Europe.
authors: P
authors: P
authors: Maass
authors: Boehringer Ingelheim Pharma GmbH & Co KG, BDM, Europe.
authors: R
authors: R
authors: Gössl
authors: SUISAG, Sempach, Switzerland.
authors: C
authors: C
authors: Schaller
authors: University of Veterinary Medicine, Hannover, Germany.
authors: D
authors: D
authors: Waberski
mesh_terms: D000818:Animals; D017925:Circovirus / Q000276:immunology*; D008297:Male; D012661:Semen / Q000187:drug effects*; D055101:Semen Analysis; D013552:Swine / Q000276:immunology / Q000502:physiology*; D014611:Vaccination / Q000009:adverse effects / Q000662:veterinary*; D014765:Viral Vaccines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D014765:Viral Vaccines
keywords: Artificial insemination; Boar; PCV2; Semen quality; Vaccination